Method Development and Validation for the Simultaneous Estimation of Ambrisentan in Tablet Dosage form by HPLC by Mustafa, Hamid
METHOD DEVELOPMENT AND VALIDATION FOR THE 
SIMULTANEOUS ESTIMATION OF AMBRISENTAN IN TABLET 
DOSAGE FORM BY HPLC  
Dissertation Submitted to 
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
In partial fulfillment for the award of the degree of 
MASTER OF PHARMACY 
In 
(Pharmaceutical Analysis) 
Submitted By 
MUSTAFA HAMID 
Reg.No: 261430012                                                                                                
Under the Guidance of 
 
Dr. N.Ramalakshmi, M.Pharm., Ph.D 
Assistant Professor 
 
 
 
DEPARTMENT OF PHARMACEUTICAL ANALYSIS 
C.L. BAID METHA COLLEGE OF PHARMACY 
(An ISO 9001-2000 certified institute) 
THORAIPAKKAM, CHENNAI – 600097 
OCTOBER  - 2016 
  
Dr. N.Ramalakshmi, M.Pharm., Ph.D 
Department of Pharmaceutical Analysis  
 
 
CERTIFICATE 
 
 
 This is to certify that the project entitled, “METHOD DEVELOPMENT AND 
VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF AMBRISENTAN IN 
TABLET DOSAGE FORM BY HPLC ” submitted by Regd. No.261430012  in partial 
fulfillment for the award of degree of Master of Pharmacy (Pharmaceutical Analysis). The 
project was carried out at IDEAL ANALYTICAL LAB, PONDYCHERRY and C.L.Baid 
Metha college of Pharmacy, Chennai-97 under my supervision during the academic year 
2015-2016. 
 
 
 
 
Date:       Dr. N.Ramalakshmi, M.Pharm., Ph.D 
       Assistant Professor 
Place: Chennai-97   Department of Pharmaceutical Analysis 
C.L.Baid Metha college of Pharmacy 
Chennai-600097 
  
 
Dr. C.N NALINI M. Pharm., Ph.D 
Prof and HOD of pharmaceutical analysis 
 
 
CERTIFICATE 
 
 This is to certify that the project entitled  “METHOD DEVELOPMENT AND 
VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF AMBRISENTAN IN 
TABLET DOSAGE FORM BY HPLC”  submitted by Regd. No. 261430012 in partial 
fulfillment for the award of degree of Master of Pharmacy (Pharmaceutical Analysis). The 
project was carried out at IDEAL ANALYTICAL LAB PONDYCHERRY and C.L.Baid 
Metha college of Pharmacy, Chennai-97 under the guidance of Dr. N.Ramalakshmi, 
M.Pharm., Ph.D during academic year 2015-2016 
 
 
Date:       Dr. C.N NALINI M. Pharm., Ph.D 
            Professor and Head of the Department 
Place:  Department of Pharmaceutical Analysis 
C.L.Baid Metha college of Pharmacy 
Chennai-600097 
 
  
 
Dr. Grace Rathnam, M.Pharm., Ph.D  
Principal 
       
      CERTIFICATE 
 
This is to certify that the project entitled “METHOD DEVELOPMENT AND 
VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF AMBRISENTAN IN 
TABLET DOSAGE FORM BY HPLC”  submitted by Regd. No. 261430012 in partial 
fulfillment for the award of degree of Master of Pharmacy (Pharmaceutical Analysis). The 
project was carried out at IDEAL ANALYTICAL LAB PONDYCHERRY and C.L.Baid 
Metha college of Pharmacy, Chennai-97 under the guidance of Dr. N.Ramalakshmi, 
M.Pharm., Ph.D during academic year 2015-2016 
 
 
 
Date:       Dr. Grace Rathnam M. Pharm., Ph.D 
Place:       Principal                                                                           
                                                                              C.L.Baid Metha College of Pharmacy, 
     Chennai - 600097. 
 
      
  
DECLARATION 
 
 
 I hereby declare that this dissertation entitled, “METHOD DEVELOPMENT AND 
VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF AMBRISENTAN IN 
TABLET DOSAGE FORM BY HPLC”  has been originally carried out by me under the 
guidance and supervision of Dr. N.Ramalakshmi,  M.Pharm., Ph.D. Department of 
Pharmaceutical Analysis, C.L.Baid Metha College of Pharmacy, Chennai – 97 during the 
academic year 2013-2015. The work embodied in this thesis is original, and is not submitted 
in part or full for any other degree of this or any other University. 
 
 
 
 
 
 
Date:               [Reg. No: 261430012] 
Place:                         Dept. of pharmaceutical analysis 
 
 
 
 
 
 
 
 
 
 
 Acknowledgement 
“Success is how high you bounce when you hit bottom” 
“If you can dream it, you can do it” 
It affords me an immense pleasure to acknowledge with gratitude the help and 
guidance rendered to me by a host of people, whom, I owe a substantial measure for the 
completion of the dissertation. 
Firstly, I glad to have the blessings of God and my Father in the implementation 
of our thought of doing this project.  I thank God for providing me strength and power to 
overcome all the hurdles and hindrances that come in the way of doing the project work. 
I take this golden opportunity to express my humble gratitude and respect to my 
research guide Dr. N.Ramalakshmi,   M.Pharm., Ph.D. Assistant professor, 
Department of Pharmaceutical Analysis, C.L.Baid Metha College of Pharmacy, 
Chennai – 97, for her inspiring guidance, constant encouragement and intellectual 
suggestions throughout the course of the dissertation. 
I express our profound sense of gratitude to our honorable Principle Dr. Grace 
rathnam, M.pharm., Ph.D Principal, and Head of the Department of 
Pharmaceutics 
It is my privilege to express my grateful and sincere thanks to Dr. C.N NALINI 
M. Pharm., Ph.D, Professor and Head of the Department of Pharmaceutical 
analysis, C.L.Baid Metha College of Pharmacy. 
This is my great privilege to thank Dr. Shantha Arcot M.sc Pharmacy Ph.D 
for her great support and motivation for completing my project. 
I would like to use this opportunity to thank Managing Director 
K.Maruthappapandian, R.Parmaguru, Ideal Analytical and Research Institution 
Pondicherry for their kind co-operation rendered in fulfilling my work. 
 
 
  
I extend my sincere thanks to Librarian M.Rajalakskmi C.L Baid Metha College 
of Pharmacy in helping me to utilize the library facilities for references. I thank all non-
teaching staff members of our college including Mrs R.Usha, Mrs Valli and Mrs A.P. 
Kalpakam for their help extended during my project work. 
I profusely thank to all my classmates and juniors for their timely help and good 
wishes. And also I thank one and all, who helped me directly or indirectly for the 
successful completion of my project work. 
Last but not least I am highly grateful and dedicated to my Mom (Maa) and my 
brothers for their moral support. 
 
 
 
      MUSTAFA HAMID 
       Reg.No: 261430012                                                                                                
      Dept. of pharmaceutical Analysis  
 
Date:  
Place: 
  
 CONTENTS 
 
CHAPTER 
NO. 
TITLE 
PAGE 
NO. 
1 INTRODUCTION  
2 LITERATURE REVIEW   
3 
AIM AND OBJECTIVE  
PLAN OF WORK  
4 DRUG PROFILE  
5 MATERIALS AND EQUIPMENTS  
6 
ANALYTICAL METHOD DEVELOPMENT 
AND OPTIMIZTION 
 
7 VALIDATION OF DEVELOPED METHOD  
8 SUMMARY AND CONCLUSION  
9 BIBLIOGRAPHY  
 
 
 
 
 
LIST OF TABLES 
 
TABLE 
NO. 
TITLE 
PAGE 
NO. 
1 Suitable parameters for HPLC method development  
2 
Comparison of Validation Parameters Required for HPLC 
Assay Methods 
 
3 List of Instruments  
4 List of Chemicals  
5 List of Standard drugs  
6 Marketed formulation  
7 List of Apparatus  
8 Results for trial 1  
9 Results for trial 2  
10 Results for trial 3  
11 Results for trial 4  
12 Results for trial 5  
13 Results fortrial 6  
14 Chromatographic Conditions  
15 Tabular Column for the Assay of Marketed formulation  
16 HPLC Chromatogram of blank (mobile phase)  
17 Linearity of Ambrisentan  
18 Accuracy results for Ambrisentan  
19 Precision results for Ambrisentan  
20 Lod and Loq Determination  
21 Result of flow rate change  
TABLE 
NO. 
TITLE 
PAGE 
NO. 
22 Result of Column temperature change  
23 Result of pH change  
24 System suitability data of Ambrisentan  
25 Tabular Column for the Assay of Marketed formulation  
 
  
LIST OF FIGURES 
 
FIGURE 
NO. 
TITLE 
PAGE 
NO. 
1.  Schematic diagram of HPLC  
2.  Retention time  
3.  Resolution oftwo peaks  
4.  Tailing Factor  
5.  HPLC chromatogram for first trial  
6.  HPLC chromatogram for second trial  
7.  HPLC chromatogram for third trial  
8.  HPLC chromatogram for fourth trial  
9.  HPLC chromatogram for fifth trial  
10.  HPLC chromatogram for sixth trial  
11.  HPLC chromatogram of Ambrisentan for marketed formulation  
12.  HPLC Chromatogram of blank (mobile phase)  
13.  HPLC chromatogram of Placebo  
14.  HPLC chromatogram of standard Ambrisentan  
15.  HPLC chromatogram of sample   
16.  HPLC chromatogram of Ambrisentan for linearity 50%.  
17.  HPLC chromatogram of Ambrisentan for linearity 60%.  
18.  HPLC chromatogram of Ambrisentan for linearity 80%.  
19.  HPLC chromatogram of Ambrisentan linearity 100 %.  
20.  HPLC chromatogram of Ambrisentan linearity 120 %  
21.  HPLC chromatogram of Ambrisentan linearity 150 %  
22.  Linearity plot of Ambrisentan  
FIGURE 
NO. 
TITLE 
PAGE 
NO. 
23.  HPLC chromatogram of Ambrisentan for Accuracy 50% Inj (1)  
24.  HPLC chromatogram of Ambrisentan for Accuracy 50% Inj (2)  
25.  HPLC chromatogram of Ambrisentan for Accuracy 50% Inj (3)  
26.  HPLC chromatogram of Ambrisentan for Accuracy 100% Inj (1)  
27.  HPLC chromatogram of Ambrisentan for Accuracy 100% Inj (2)  
28.  HPLC chromatogram of Ambrisentan for Accuracy 100% Inj (3)  
29.  HPLC chromatogram of Ambrisentan for Accuracy 150% Inj (1)  
30.  HPLC chromatogram of Ambrisentan for Accuracy 150% Inj (2)  
31.  HPLC chromatogram of Ambrisentan for Accuracy 150% Inj (3)  
32.  HPLC chromatogram of Ambrisentan for Precision Inj (1)  
33.  HPLC chromatogram of Ambrisentan for Precision Inj (2)  
34.  HPLC chromatogram of Ambrisentan for Precision Inj (3)  
35.  HPLC chromatogram of Ambrisentan for Precision Inj (4)  
36.  HPLC chromatogram of Ambrisentan for Precision Inj (5)  
37.  HPLC chromatogram of Ambrisentan for Precision Inj (6)  
38.  
HPLC chromatogram of Ambrisentan for robustness (Flow 
0.9ml/min) 
 
39.  
HPLC chromatogram of Ambrisentan for robustness (Flow 1.1 
ml/min) 
 
40.  HPLC chromatogram of Ambrisentan for robustness (Temp 30˚C)  
41.  HPLC chromatogram of Ambrisentan for robustness (Temp 40˚C)  
42.  HPLC chromatogram of Ambrisentan for robustness (pH2.8)  
43.  HPLC chromatogram of Ambrisentan for robustness (pH 3.2)  
44.  
HPLC chromatogram of Ambrisentan for robustness (M.P Variation 
-2%) 
 
FIGURE 
NO. 
TITLE 
PAGE 
NO. 
45.  
HPLC chromatogram of Ambrisentan for robustness (M.P variation 
+2%) 
 
46.  
HPLC chromatogram of Ambrisentan for solution stability after 24 
hrs 
 
47.  
HPLC chromatogram of Ambrisentan for solution stability after 48 
hrs 
 
48.  HPLC chromatogram of Ambrisentan for marketed formulation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
AUC Area under concentration 
Conc. Concentration 
FDA Food and drug administration 
gms Gram 
hrs Hours 
ICH International conference on harmonization 
LOD Limit of detection 
LOQ Limit of quanitation 
mg Milli gram 
mL Milli liters  
Mins Minutes 
mm Milli meter 
ng Nano gram 
NLT Not less than 
nm Nano meter 
NMT Not more than 
ODS Octadecylsilane 
PAH Pulmonary arterial hypertension 
Psi Pascal per square inch 
RP-HPLC Reverse phase high performance liquid chromatography 
RSD Relative standard deviation 
Rt Retention time 
S. No. Serial number 
Std.Dev Standard deviation 
USP United states pharmacopoeia  
UV Ultra violet 
µL Micro liters 
µm Micro meters 
µg (or) mcg Micro gram 
0C Degree Celsius  
% Percentage 
 
 
 Department of Pharmaceutical Analysis 2016 
 
C. L. Baid Metha College of Pharmacy Page 1 
 
1. INTRODUCTION 
 
 Pharmaceutical analysis plays a vital role in the Quality Assurance and Quality 
control of bulk drugs. Analytical chemistry involves separation, identification, and 
determining the relative amounts of components in a sample matrix; Pharmaceutical 
analysis is a specialized branch of analytical chemistry that derives its principles from 
various branches of sciences like physics, microbiology, nuclear science, and electronics 
etc. Qualitative analysis is required before a quantitative analysis can be undertaken. 
 Analytical method development and validation is a good research in the field of 
Pharmaceutical analysis, utilized to determine the drug content in bulk and pharmaceutical 
dosage forms and in biological fluids like blood, serum, urine etc. In view of the industrial 
scenario and literature, it was noted that chromatographic techniques like HPLC, LC–
MS/MS methods have created revolutionary precision and accuracy in quantification of 
drugs in Formulation and in Biological fluids even at low concentration. 
Need for pharmaceutical Analysis 
 New drug development. 
 Method Validation as for ICH Guidelines 
 Research in Pharmaceutical Sciences 
 Clinical Pharmacokinetic Studies 
 
1.1 Chromatographic Techniques 
Recently, the IUPAC has defined chromatography as; “Methods used primarily for 
the separation of the components of a sample, in which the components are distributed 
between two phases, one of which is stationary while other moves. The stationary phase may 
be a solid or a liquid supported on a solid or a gel, and may be packed in a column, spread as 
a layer or distributed as a film. The mobile phase may be gaseous or liquid”.
1
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M.T Swett coined the term "chromatography" to describe the process of separating 
colorful leaf pigments in a column made of chalk.2 Chromatography is a non-destructive 
technique used for separating a mixture of compounds into individual components using a 
stationery phase and mobile phase.3 Chromatography is used routinely in almost every 
laboratory for a large number of tasks. These range from the separationof mixtures on an 
analytical as well as preparative scale, purification and pre concentration of an analyte to 
controlling the progress of a chemical reaction. 
Classification of Chromatographic Techniques  
 According to the nature of stationary and mobile phase  
 Gas Solid Chromatography  
 Gas Liquid Chromatography  
 Solid Liquid Chromatography  
 Liquid Liquid Chromatography  
 
 According to mechanisms of separation, chromatographic methods are divided into 
 Adsorption chromatography 
 Partition chromatography 
 Ion exchange chromatography  
 Ion pair chromatography  
 Size exclusion or gel permeation chromatography  
 Affinity chromatography  
 Chiral phase chromatography  
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1. Adsorption chromatography 
 The principle of separation is adsorption. Separation of components takes place 
because of the difference in affinity of compounds towards stationary phase. This principle 
is seen in normal phase as well as reverse phase mode, where adsorption takes place. 
2. Partition chromatography 
 When two immiscible liquids are present, a mixture of solutes will be distributed 
according to their Partition co efficient .When a mixture of compounds are dissolved in the 
mobile phase and passed through a column of liquid stationery phase, the component which 
is more soluble in the stationery phase travels slower. The component which is more soluble 
in the mobile phase travels faster. Thus the components are separated because of the 
differences in their partition co- efficient. No two components have the same partition co-
efficient for a particular combination of stationery phase, mobile phase and other conditions. 
The stationery phase as such cannot be a liquid 
3. Ion exchange chromatography 
 The principle of separation is ion exchange, which is  reversible exchange of 
functional groups. In ion exchange chromatography, an ion exchange resin is used to 
separate a mixture of similar charged ions. For cations, a cations exchange resin is used. For 
anions, an anion exchange resin is used.   In ion exchange chromatography, the stationary 
solid phase of the chromatographic column (or sheet or other device) commonly consists of 
a resin with covalently attached anions or cat ions.4When the sample, dissolved in water or 
another liquid, is run over the column, sample ions of the opposite charge are attracted to the 
stationary ions of the column by electrostatic forces and weakly bind to them. Adsorbed 
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sample components are then eluted by application of a salt gradient which gradually desorbs 
the sample molecules in order of increasing electrostatic interaction with the ions of the 
column. 
4. Ion pair chromatography 
 In ion pair chromatography, a reverse phase column is converted temporarily into 
ion exchange column by using ion pairing agents like pentane or hexane or heptanes or 
octane sulphonic acid sodium salt, tetraethyl or tetra methylhydroxide etc. 
5. Size exclusion or gel permeation chromatography 
 In this type of chromatography, a mixture of components with different molecular 
sizes is separated by using gel. The gel used acts as molecular sieve and hence mixture of 
substances with different molecular sizes is separated. Soft gels like dextran are also  used.    
6. Affinity chromatography: 
 Affinity chromatography uses the affinity of the sample with specific stationary 
phases. This technique is mostly used the field of biotechnology, micro biology, 
biochemistry etc. 
7. Chiral phase chromatography 
 Separation of optical isomer can be done by using chiral stationary phases different 
principles operate for different types of stationary phases and different samples. The 
stationary phases are used for this type of chromatography are mostly chemically bonded 
silica gel. 
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In chromatographic separation, HPLC and HPTLC methods have widely been exploited in 
pharmaceutical analysis because of its simplicity, precision, accuracy and reproducibility of 
results.
1 
1.2 INTRODUCTION TO HPLC 
High performance liquid chromatography is basically a highly improved form of column 
chromatography. Instead of a solvent being allowed to drip through a column under gravity, 
it is forced through under high pressures of up to 400 atmospheres.  
HPLC allows the use of very small particle size for the column packing material 
which gives a much greater surface area for interactions between the stationary phase and 
the molecules flowing past it. This allows a much better separation of the components of the 
mixture. Its simplicity, high specify and wide range of sensitivity makes it ideal for analysis 
of many drugs in both dosage forms and in biological fluid. 
 
1.3 TYPES OF HPLC TECHNIQUES  
A. Based on modes of separation: There are two modes, normal phase mode and reverse 
phase mode5. 
i) Normal phase mode: In this mode, the stationary bed is strongly polar in nature (e.g., 
silica gel), and the mobile phase is nonpolar (such as n-hexane or tetrahydrofuran). Polar 
samples are thus retained on the polar surface of the column packing longer than less polar 
materials. 
ii) Reveres phase modeReverse-phase chromatographyis the inverse of Normal phase 
mode. The stationary bed is nonpolar (hydrophobic) in nature, while the mobile phase is a 
polar liquid, such as mixtures of water and methanol or acetonitrile. Here the more nonpolar 
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the material is, the longer it will be retained.Non-polar compounds in the mixture will tend 
to form attractions with the hydrocarbon groups because of vanderwaals dispersion forces. 
Since most of the drugs and pharmaceuticals are polar in nature, they are not retained for a 
longer time and eluted faster which is advantageous. Different columns used are ODS 
(octadecylsilane), C18, C8, C4 etc. 
B. Based on elution technique 
Isocratic separation In this technique the same mobile phase combination is used 
throughout the process of separation, the same polarity or elution strength is maintained 
through the process. 
Gradient separationIn this technique, a mobile phase combination of low polarity or 
elution strengths is used followed by gradually increasing the polarity or elution strengths. 
C. Based on the scale of operation:- 
Analytical HPLCIn this technique only analysis of the samples are done. Recovery of the 
samples for reusing is normally not done, since the sample used very low. Ex. µgm 
quantities. 
Preparative HPLCIn this technique individual fraction of pure compounds can be collected 
using fraction collector. The collected samples are reused. Ex. Separation of few grams of 
mixtures by HPLC. 
D. Based on the type of analysis 
Qualitative analysisIt is done to identify the compound, detect the presence of impurity, to 
find out the number of components etc... This is done by using retention time values. 
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Quantitative analysisItis doneto determine the quantity of the individual or several 
components in a mixture.  This is done by comparing the peak area of the standard and 
sample.  
1.4  PRINCIPLE OF HPLC 
The principle of separation in normal phase mode and reverse phase mode is adsorption 
and/or partition. 
ADSORPTION 
           When a mixture of components is introduced in to a HPLC column they travel 
according to their relative affinities towards the stationary phase. The component which has 
more affinity towards the stationary phase travels slower. The component which has less 
affinity towards the stationary phase travels faster. Since no two components have the same 
affinity towards the stationary phase the components are separated 
PARTITION 
  When a mixture of compounds are dissolved in the mobile phase and passed 
through a column of liquid stationery phase, the component which is more soluble in the 
stationery phase travels slower. The component which is more soluble in the mobile phase 
travels faster. Thus the components are separated because of the differences in their partition 
co-efficient. No two components have the same partition co-efficient for a particular 
combination of stationery phase, mobile phase and other conditions. 
1.4 INSTRUMENTATION OF HPLC 
The main components of HPLC system are as follows  
 Department of Pharmaceutical Analysis 2016 
 
C. L. Baid Metha College of Pharmacy Page 8 
 
a) Mobile phase reservoir  
b) pumps  
c) Sample mixing units 
d) Sample injectors  
e) Column 
f) Detectors. 
g) Recorders and injectors 
 
 
Fig No 1: Schematic diagram of HPLC 
a) Mobile phase Reservoirs The modern HPLC apparatus is equipped with one or more 
glass or stainless steel reservoirs each of which contains 200-1000ml of a solvent. The 
mobile phase are often equipped with a mean of removing dissolved gasses usually oxygen 
or nitrogen. These bubbles cause band spreading, in addition they often interfere with 
performance of the detectors. Often the systems also contain a means of filtering dust and 
particulate matter from the solvent to prevent these particles from damaging the pumping 
systems or clogging systems. This treatment removes gases as well as suspended matter. A 
separation that employs a single solvent of constant composition is termed as isocratic 
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elution. Frequently separation efficiency is greatly enhanced by gradient elution. Here two 
difference solvent systems that differ significantly on polarity are employed.   
b) PumpsThe most important component of HPLC in solvent delivery systems is the pumps 
because its performance directly affects the retention time reproducibility and detector 
sensitivity.  
Three types of pumps each with its own set of advantages are encountered namely. 
 Reciprocating pumps 
 Displacement –type pumps  
 Pneumatic pumps 
i) Reciprocating Pumps 
They usually consist of chamber in which the solvent is pumped by the back and forth 
motion of a motor drive piston. The two ball check valves which open and close alternately 
control the flow of solvent in to and (close alternately control the flow of solvent in to and) 
out of a cylinder track with the piston. 
ii) Displacement Pumps              
           Displacement pump consist of large, syringe like chambers equipped with a 
plunger that is activated by a screw driven mechanism powered by a stepping metor. The 
output is pulse free.  
iii) Pneumatic Pumps 
            The pneumatic pumps, the melphis contained in a compatible container housed 
in a vessel that can be pressurized by compressed gas. Pumps of this type are in expensive 
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and pulse free6-7, they suffer from limited capacity and pressure output as well as a 
dependence of flow rate on solvent viscosity and column back-pressure. In addition they are 
not amiable to gradient elution and are limited to pressure less than about 2000psi.  
c) Flow Control and Programming Systems 
As part of their pumping systems, many commercial instruments are equipped with 
computer controlled devices for measuring the flow rate by determining the pressure drop 
across a restrictor located at the pump outlet. 
 d) Sample Mixing Units 
Mixing unit is used to mix solvents in different proportions and pass through the column. 
They are Low pressure mixing chamber which uses helium for degassing solvents and High 
pressure mixing chamber does not require helium for degassing solvents. 
e) Sample Injector 
Often the limited factor in the precision of liquid chromatographic measurement lies in the 
reproducibility with which samples can be introduced in to columns packing. Exaggerated 
by band broadening which accompanies overloading columns. These volumes used must be 
minuscule a (Thus, the volumes used must be mini) of a ml to perhaps 500ml.It is 
convenient to be able to introduce the sample without depressurizing the system. 
f) Columns  
HPLC columns are ordinarily constructed from smooth-bore stainless steel tubing, although 
heavy-walled glass tubing is occasionally encountered. 
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Analytical columns 
The majority of HPLC columns range in length from 10-30cm. Normally columns are 
straight with added length when needed, being gained by coupling two or more columns 
together occasionally called columns are encountered   
 The inside diameter of liquid column is often 2-5mm.The most common particles 
size of packed columns is 5-10µm .the most common columns currently in use is one that is 
15-25cm in length,4.6mm inside diameter ,and packed with 5µm particles. Columns of this 
type contain 4000-6000plates/meter. 
Guard columns 
 The guard columns have very small quantity of adsorbent and improve the life of 
the analytical columns. It also acts as a prefilter to remove particulate matter and any other 
material. Guard column has the same material as that of analytical column but does not 
contribute to any separation. 
g) Column thermostats 
For many applications close control of column temperature is not necessary and columns are 
appareled at combined temperature often. However better chromatograms are obtained by 
monitoring column temperature constant to few degree centigrade. Most modern 
commercial instruments are now equipped with column heaters that control, column 
temperature to a few tenths of degree from near obtained to 100-150 ºc. Columns may also 
be fitted with water jackets fed from a constant temperature bath to give precise temperature 
control.  
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h) Column material 
The columns are made up of either stainless steel glass polyethylene, PEEK (poly ether 
ether ketone). Most widely used are stainless steel which can with stand high pressure. 
Latest ones are PEEK columns whose length varies from 5-30cm, diameter ranges from 2-
5mm and particle size from 1µ-20µ.Particle should be spherical and uniform in nature. 
Porous materials are used. Surface area of 1gm of stationary phase provides surface area 
ranging from 100-860 mts. 
i) Functional group 
 The functional group present in stationary phase depends on the type of 
chromatographic separation in normal phase mode it contain following groups  
o C18 –octadecylSilane (ODS) column 
o C8-octylcolumn   
o C4-butyl column   
o CN-cyano column   
o NH2-amino column   
j) DETECTORS  
The function of detector in HPLC is to monitor the mobile phase as it emerges through the 
column 
Types of detectors  
i) Absorbance detectorA ‘Z’ shaped flow through cell for absorbance measurement on 
elements from a chromatographic column in order to minimize extra column band 
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broadening the volume of such a cell is kept as small as possible. The typically 
volumes are limited to 1-10µl and cell length to 2-10mm here intensity of the solvent 
system are stored in a computer memory and ultimately recalled for the calculation of 
absorbance.  
ii) UV detectorUV detector is based on the light absorption characteristics of sample. Two 
types of this detector are, one is the fixed wavelength detector which operates at 254nm, 
and other is variable wavelength detector which can be operated from 190nm to 400nm.  
iii) Refractive index detector This is a nonspecific or universal detector. This is not much 
used for analytical applications because of low sensitivity and specificity.   
iv) Flourimetric detector Flourimetric detector is based on fluorescent radiation emitted by 
some class of compound. In most cases fluorescence is absorbed by a photoelectric 
detector located at 90ºto the excitation beam. The simplest detectors employ a mercury 
excitation sources and one or more filters to isolate a band of emitted radiation. This 
detector has more sensitivity and specificity.  
v) Conductivity detector Based upon electrical conductivity, the response is recorded. 
This detector is used when the sample has conducting ions like anions and cat ions  
vi) Amperometric detector Amperometric detector is based on the reduction or oxidation 
of the compounds when a potential is applied. The diffusion current recorded is 
proportional to the concentration of the compound eluted this is applicable when 
compounds have functional group which can be either oxidized or reduced this is a 
highly high sensitive detector. 
vii) PDA detectorPDA detector is a recent one which is similar to UV detector which   
operates from 190-600nm. Radiations of all wavelengths fall on the detector 
simultaneously. The resulting spectrum is 3-D or three dimensional plot of response Vs 
time Vs wavelength. 
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k)  Recorders and integrators Recorders are used to record the responses obtained from 
detectors after amplification, if necessary. They record the base line and all the peaks 
obtained, with respect time to time. Retention time for all the peaks can be found out from 
such recordings, but the area of individual peaks cannot be known. 
 Integrators are improved variation of recorders with some data processing 
capabilities. They can be recorded the individual peaks with retention time, height and width 
of peaks, peak area, percentage of area, etc. 
1. 
 
 
 
 
 
1.5 GENERAL INFORMATION ON HPLC METHOD DEVELOPMENT 
 A good method development strategy should require only as many experimental 
runs as are necessary to achieve the desired final result. Finally method development should 
be as simple as possible, and it should allow the use of sophisticated tools such as computer 
modeling.  
 The important factors, which are to be taken into account to obtain reliable 
quantitative analysis, are 
a) Careful sampling and sample preparation.  
b) Precise sample injection. 
c) Appropriate choice of the column. 
d) Choice of the operating conditions to obtain the adequate resolution 
e) Reliable performance of the recording and data handling systems. 
f) Suitable integration/peak height measurement technique. 
g) The mode of calculation best suited for the purpose 
h) Validation of the developed method.  
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Separation goals: 
 The goals of HPLC separation need to be specified clearly include the use of HPLC to 
isolate purified sample components for spectral identification or quantitative analysis. It may be 
necessary to separate all degradants or impurities from a product for reliable content In quantitative 
analysis, the required levels of accuracy and precision should be known (a precision of 1 to 2% is 
usually achievable). Whether a single HPLC procedure is sufficient for raw material or one or more 
for mutations and/or different procedures are desired for formulations. When the number of samples 
for analysis at one time is greater than 10, a run time of less than 20 minutes often will be 
important.  
Getting Started On Method Development 
      One approach is to use an isocratic mobile phase of some average solvent strength 
(50%) organic solvent. A better alternative is to use a very strong mobile phase first (80-
100%) then reduce %B as necessary. 
 The initial separation with 100% B results in rapid elution of the entire sample, but few 
groups will separate. Decreasing the solvent strength shows the rapid separation of all 
components with a much longer run time, with a broadening of latter bands and reduced 
retention sensitivity. 
 Goals that are to be achieved in method development are briefly summarized in 
below table in order of decreasing importance but may vary with analysis requirements. 
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GOAL COMMENTS 
Resolution Precise and rugged quantitative analysis requires that Rs be greater 
than 1.5. 
Separation time <5-10 min is desirable for routine procedures. 
Quantitation 2% for assays; 5% for less-demanding analyses 15% for trace 
analyses. 
Pressure <150 bar is desirable, <200 bar is usually essential (new column 
assumed). 
Peak height Narrow peaks are desirable for large signal/noise ratios. 
Solvent 
consumption 
Minimum mobile-phase use per run is desirable. 
 Table No:1 Suitable parameters for HPLC method development 
1.6 VALIDATION  
The word “validation” means “Assessment” of validity or action of validity or action of 
providing effectiveness’. 
Definitions 
FDA defines validation as “establish the documented evidence which provides a high of 
assurance that a specific process will consistently produce a product of predetermined 
Specifications and quantity attributes”. 
 
 WHO action of providing that, any procedure, process, equipment, material, activity, or 
system actually leads to the expected results. 
 Department of Pharmaceutical Analysis 2016 
 
C. L. Baid Metha College of Pharmacy Page 17 
 
EUMGP define validation as “action of proving in accordance with the principle of Good 
manufacturing practice (GMP), that any material, activity or system actually lead to 
expected result”.  
AUSTRALIAN GMP defines validation as “the action of proving that any material, 
process, activity, procedure, system, equipment or mechanism and intended results”. 
1.7 METHOD VALIDATION GUIDELINES 
1.7.1 FDA guidelines 
The FDA published the draft on “Guidance for Industry on Analytical Procedures and 
Method Validation” to aid pharmaceutical companies in meeting the code of federal 
regulations requirement [FDA, 2000]. This guidance, when approved, supersedes the FDA 
Guidance for Industry on Submitting Samples and Analytical Data for Method Validation 
[FDA, 1987]. According to the FDA, analytical methods are categorized into four tests: 
identification, testing for impurities (quantitative and limit), assay (dissolution, content, 
potency), and specific tests. Recently, the Centre for Drug Evaluation and Research 
(CDER), a division of the FDA, also issued guidance for validation of bio analytical 
methods [FDA-CDER, 2001].  
1.7.2 ICH guidelines  
The ICH was initiated around 1990. It is an important regulatory initiative to standardize 
regulatory requirements between the European Community, Japan and the United States. 
Recognizing the benefits of having consistent international requirements, ICH developed a 
number of guidelines that have been recognized in these countries. The two main documents 
of ICH guidelines pertaining to analytical method validation are: 
(i) Q2A: Text on Validation of Analytical Procedures [ICH-Q2A, 1995] 
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(ii) Q2B: Validation of Analytical Procedure Methodology [ICH-Q2B, 1997] (6) 
1.7.3 USP guidelines  
The USP [USP, 2006] categorizes analytical methods into four types of tests: quantisation of 
major components of drug product, testing for impurities (quantitative and limit), 
performance characteristics and identification tests. USP refers to the same definitions of 
ICH Q2A and Q2B recommendations for procedures on meeting validation requirements.  
Table 2: Comparison of Validation Parameters Required for HPLC Assay Methods 
ICH Guidelines USP Guidelines FDA Guidelines 
Accuracy Accuracy Accuracy 
Precision Precision Precision 
Repeatability -- Repeatability 
Inter-day precision -- Inter-day precision 
Reproducibility -- Reproducibility 
Specificity Specificity Specificity 
Limit of detection Limit of detection Limit of detection 
Limit of quantification Limit of quantification Limit of quantification 
Linearity Linearity Linearity 
Range Range Range 
-- Ruggedness -- 
Robustness Robustness Robustness 
System suitability System suitability System suitability(7) 
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1.8 ANALYTICAL METHOD VALIDATION  
Method validation is the process for establishing that performance characteristics of 
the analytical method are suitable for the intended application. Chromatographic methods 
need to be validation before first routine use. To obtain the most accurate results, all of the 
variables of the method should be considered, including sampling procedure, sample 
preparation, chromatographic separation, detection and data evaluation, using the same 
matrix as that of the intended sample. The validity of an analytical method can only be 
verified by laboratory studies. All validation experiments used to make claims or 
conclusions about validity of the method should be documented in report. 
Types of analytical procedures to be validated  
 Identification test for impurities 
 Quantitative test for impurities 
 Limit test control of impurities  
 Quantitative test for the active moiety in samples of drug substance or drug product, 
or other selected components (s) in the drug product.  
 Dissolution testing.  
1.9 VALIDATION PARAMETERS AS PER ICH & FDA GUIDELINES 
1.9.1 Specificity:  
Specificity is the ability to assess unequivocally the analyte in the presence of components, 
which may be expected to be present. Typically, these might include impurities, degradants, 
matrix, etc. For formulation assay, a sample matrix may include impurities, degradation 
products, excess raw materials, or excipients. The chromatographic method should be 
 Department of Pharmaceutical Analysis 2016 
 
C. L. Baid Metha College of Pharmacy Page 20 
 
specific and sensitive as required for all known relevant degradation products and/or 
impurities. 
Lack of specificity of an individual analytical procedure may be compensated by other 
supporting analytical procedures 
This definition has the following implications: 
Identification : to ensure the identity of an analyte. 
Purity Tests : to ensure that all the analytical procedures performed allow an 
accurate statement of the content of impurities of an analyte, i.e. 
related substances test, heavy metals, residual solvents content, etc. 
Assay (content or potency):  to provide an exact result which allows an accurate 
statement on the content or potency of the analyte in a 
sample. 
1.9.2 Linearity: 
The linearity of an analytical procedure is its ability (within a given range) to obtain test 
results which are directly proportional to the concentration (amount) of analyte in the 
sample. A range of standards should be prepared containing at least 5 different 
concentrations of analyte, which are approximately evenly spaced, and span 80-120% of the 
label claim. 
Acceptance criteria: 
Correlation coefficient should be not less than 0.9990. 
% of y-intercept should be ± 2.0.  % of RSD for level 1 and level 5 should be not more 
than± 2.0 
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1.9.3 Range: 
The range of an analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample (including these concentrations) for which 
it has been demonstrated that the analytical procedure has a suitable level of precision, 
accuracy and linearity. 
The specified range is in general derived from linearity studies and depends on 
the intended application of the procedure. It is established by confirming that the analytical 
procedure provides an acceptable degree of linearity, accuracy and precision when applied to 
samples containing amounts of analyte within or at the extremes of the specified range of the 
analytical procedure. 
The following minimum specified ranges should be considered: 
 For the assay of a drug substance or a finished (drug) product: normally from 80 to120 
percent of the test concentration. 
 For content uniformity, covering a minimum of 70 to 130 percent of the test 
concentration, unless a wider more appropriate range, based on the nature of the dosage 
form (e.g., metered dose inhalers), is justified. 
 For dissolution testing: +/-20 % over the specified range. 
1.9.4 Accuracy 
The accuracy of an analytical procedure expresses the closeness of agreement between the 
value, which is accepted either as a conventional true value or an accepted reference value 
and the value found.  
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The accuracy may be determined by application of analytical method to an analyte 
of known purity (example: reference standard) and also by comparing the results of the 
method with those obtained using an alternate procedure that has been already validated. 
The true value for accuracy assessment can be obtained in several ways and the 
value found as: 
One method is to compare the results of the method with results from an established 
reference method. This approach assumes that the uncertainty of the reference method is 
known. 
Secondly, accuracy can be assessed by analyzing a sample with known concentrations and 
comparing the measured value with the true value as supplied with the material. 
Third method if certified reference materials or control samples are not available, a 
blank sample matrix of interest can be spiked with a known concentration by weight or 
volume. After extraction of the analyte from the matrix and injection into the analytical 
instrument, its recovery can be determined by comparing the response of the extract with the 
response of the reference material dissolved in a pure solvent. Because this accuracy 
assessment measures the effectiveness of sample preparation, care should be taken to mimic 
the actual sample preparation as closely as possible.  At each recommended level studied, 
replicate samples are evaluated. Accuracy should be assessed using a minimum of 
determinations over a minimum of 3 concentrations (3 replicates each of the total analytical 
procedure). Validation and as well the accuracy should be within the range 98-102%.  
1.9.5 Precision 
The precision of an analytical procedure expresses the closeness of agreement between a 
series of measurement obtained from multiple sampling of the same homogenous sample 
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under the prescribed conditions. Precision of an analytical procedure is usually expressed 
the variance, standard deviation of coefficient of variation of a series of measurement. 
Precision may be considered at three levels: repeatability, intermediate precision and 
reproducibility. Precision should be investigated using homogeneous, authentic samples. 
However, if it is not possible to obtain a homogeneous sample it may be investigated using 
artificially prepared samples or a sample solution. 
For a good method precision, the intra-day and inter-day precisions should be within 
the acceptance criteria of % RSD ≤2.0 respectively.  
1.9.5.1 Repeatability 
Repeatability expresses the precision under the same operating conditions over a short 
interval of time. Repeatability is also termed intra-assay precision. 
1.9.5.2 Intermediate precision 
Intermediate precision expresses within-laboratories variations: different days, different 
analysts, different equipment, etc. 
1.9.5.3 Reproducibility  
Reproducibility expresses the precision between laboratories (collaborative studies, usually 
applied to standardization of methodology).  
1.9.6 Limit of detection & Limit of quantification  
The LOD of an individual analytical procedure is the lowest amount of analyte in a sample, 
which can be detected but not necessarily quantified as an exact value. The LOQ of an 
individual analytical procedure is the lowest amount of analyte in a sample, which can be 
quantitatively determined with suitable precision and accuracy. The typical methods 
recommended by ICH to determine the LOD and LOQ are: 
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(i) Signal-to-noise ratio: The LOD and LOQ can be expressed as a concentration at a 
specified signal-to-noise ratio obtained from samples spiked with analyte. 
(ii) Standard deviation of the response and the slope of the calibration curve(s) at levels 
approximating the LOD: LOD was defined as 3.3σ/S and LOQ as 10σ/S, where S is 
the slope of the calibration curve and σ is the standard deviation that can be 
determined based on the standard deviation of the blank, on the residual standard 
deviation of the regression line, or the standard deviation of y-intercepts of the 
regression lines. 
1.9.7 Ruggedness 
Ruggedness is the degree of reproducibility of test results obtained by the analysis of the 
same samples under a variety of test conditions such as different laboratories, analysis, 
instruments, reagent lots, elapsed assay times, temperature, days etc. 
It can be expressed as lack influence of the operation and environmental variable on the test 
results of the analytical method. 
1.9.8 Robustness 
It is measure of capacity of an assay to remain unaffected by small but deliberate variation 
in method parameters and provide an indication of its reliability in normal usage 
degradation and variation in chromatography columns; mobile phase and inadequate method 
development are common causes of lack of robustness.  
1.10 Parameters in Chromatography  
A good resolution of components is achieved by optimization of various parameters such as 
Resolution (Rs), number of theoretical plates (N), capacity factor (k'), and peak asymmetry 
factor (AF), etc.12
 
 Department of Pharmaceutical Analysis 2016 
 
C. L. Baid Metha College of Pharmacy Page 25 
 
 Retention time (Rt) 
Retention time is the difference in time between the point of injection and appearance of 
peak maxima. Retention time is the time required for 50% of a component to be eluted from 
a column. Retention time is measured in minutes or seconds. Retention time is also 
proportion to the distance moved on a chart paper; which can be measured in cm or mm. 
 
Figure No 4: Retention time 
 Retention volume (Rv) - Retention volume is the volume of carrier gas required 
to elute 50% of the component from the column. It is product of retention time and 
flow rate. 
   Retention volume = retention time X flow rate 
 Separation factor (S):- 
                Separation factor is the ratio of partition co-efficient of the two components 
to be separated. It can be expressed and determined by using the following equation: 
                     S= Kb/KA=Ka/Kb= (tb-to)/ (ta-to) 
Where to =retention time of unretained substance 
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Kb, Ka=partition coefficients of b and a 
Tb, ta=retention time of substance band a 
S= depends on liquid phase, column temperature 
 If there is more difference in partition coefficient between two compounds, the 
peaks are far apart and the separation factors are less. 
 Capacity factor (k')  
It is the measure of how well the sample molecule is retained by the column during an 
isocratic separation. It is affected by solvent composition, separation and aging and 
temperature of separation. 
K’ =   V1-V0 /V0 
Where V
1 
= retention volume at apex of the peak  
            V
0 
= void volume of system where an unretained component elutes 
 Column efficiency (N)  
It is called as number of theoretical plates. It measures the band spreading of a peak. When 
band spread is smaller, the number of theoretical plate is higher. It indicates to good column 
and system performance.  
N = 16 (R
t
/W) 
2
 
Where, R
t
= Retention time  
             W = Width of peak  
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Width of peak can be calculated using different methods of calculations. Column efficiency 
should be measured under ideal conditions of column, mobile phase and flow rate used. All 
these factors affect column efficiency. 
 Selectivity (α)  
It measures relative retention of two components. Selectivity is the function of 
chromatographic surface (column), melting point and temperature. 
α = K’2/K’1= V2– V0/V1-V0 
 Resolution  
It is a measure of separation between adjacent peaks in chromatogram. The amount of 
separation between 2 peaks is a function of 2 parameters. As the difference between 
retention time of peak increases, the separation also increases. Resolution is proportional to 
difference in retention times of peaks. The amount of separation depends on that portion of 
width of each peak which is nearest to the adjacent peak. As half width of peak increases, 
the amount of separation between peaks decreases and resolution also decreases.  
Rs = 2(Rt
2 
– Rt
1
) / W
2 
– W 
Where, Rt
1
, Rt
2 
– retention times of components  
            W
1
, W
2 
– width of two adjacent peaks 
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Figure No 5: Resolution oftwo peaks 
 Peak asymmetric or Tailing Factor  
A
F 
= b/a (at 10% or 5% of peak height) 
 
Figure No 6 :Tailing Factor 
 Ideal Valves  
K' = 2-10 results in good separation  
α = 2 good peak separation results  
N = 3000-10,000 plates/ column  
R
S 
= 1.5 A good baseline separation occurs  
AF = 0.95 – 1.05  
If K increases – R
S 
increases but peak becomes broadens  
    K decreases – R
S 
decreases but peak becomes sharper  
If N decreases – R
S 
decreases because peak width broadens  
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    N increases – R
S 
increases because peak width narrows 
If α increases – R
S 
increases because peak moves in relation to anterior.
13
 
Tailing factor establishes the maximum permissible asymmetry of the peak.  
T = W / 2 × F 
Where: T = Tailing factor  
W= Peak width at 5% of peak height  
F = time from width start point at of peak height to retention time (Rt) 
 
 Mean Value (Average)  
It is a measure of the location of the data. It is simply the arithmetic average of data add 
them all up and divide by the number of data points. The mean of a set of data is usually 
considered the best estimate of the value.
14 
 
Where X =mean, n=no of value 
 Standard Deviation  
It is a measure of the spread of data around the sample mean – a precision measure. It is 
always in the same units as the mean. Like the mean, it is considered an estimate of the 
population standard deviation. 
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Where S (Xi) =standard deviation, X=mean, n=no of values 
 Relative Standard Deviation  
Relative standard deviation is a measure of the spread of data in comparison to mean of the 
data. It is simply the standard deviation divided by the mean value. 
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2. LITERATURE REVIEW 
1. RamakrishnaNirogiet.al.,15 developed a LC-ESI-MS/MS method for quantification of  
ambrisentan in plasma and application to rat pharmacokinetic study. The analyte and the 
internal standard (armodafinil) were extracted from plasma by acetonitrile precipitation and 
they were separated on a reversed-phase C(18) column with a gradient program. The assay 
exhibited a linear dynamic range of 1-2000 ng/mL for ambrisentan in plasma. Acceptable 
precision (<10%) and accuracy (100 ± 8%) were obtained for concentrations over the 
standard curve range.  
2. Douaja M et.al.,16 developed a method for rapid determination of ambrisentan 
enantiomers by enantio selective liquid chromatography using cellulose-based chiral 
stationary phase in reverse phase mode. Six chiral columns were tested in a reversed-phase 
system. Excellent enantiomeric separation with the resolution more than 2.5 was achieved 
on Chiralcel OZ-3R (cellulose 3-chloro-4-methylphenylcarbamate) using mixture of 20 mM 
sodium formate (pH 3.0) with acetonitrile (55:45., v/v).  
3. Klivickyet.al.,17 developed a LC/MS/MS method for determination of ambrisentan, 
midazolam and its metabolite in human plasma. After solid phase extraction on a Strata-X 
(Phenomenex) SPE column, the analytes were separated on a Synergi MAX-RP (150×4.6 
mm, 4 µm) (Phenomenex) analytical column using isocratic elution with acetonitrile/5mM 
ammonium acetate 41:59 (v/v) as a mobile phase.Detection was achieved using tandem 
mass spectrometry on a triple quadrupole mass spectrometer. Ambrisentan-d3,midazolam-
d5 and 13 C3-1-hydroxymidazolam were used as internal standards. The calibration curves 
were linear between 2.03 and 150 ng/ml for MDL (r2 = 0.9993) and OH-MDL (r2 = 0.9987) 
and between 5.40 and 400 ng/ml for ABT (r2 = 0.9974). 
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4. Jun Xia et.al.,18 developed a method for Synthesis and in vitro evaluation of ambrisentan 
analogues as potential endothelin receptor antagonists. A series of novel 2-[(4, 6-
dimethylpyrimidin-2-yl) oxy]-3, 3-diphenyl butyric acid derivatives were synthesized and 
evaluated for their antagonistic activity for endothelin-1-induced contraction in rabbit aorta. 
5. Johanna Weiss et.al.,19 made an in vitro study on Differential modulation of the 
expression of important drug metabolising enzymes and transporters by endothelin-1 
receptor antagonists ambrisentan and bosentan. LS180adenocarcinoma cells were treated for 
four days with bosentan or ambrisentan (1–50 μM), the positive control rifampicin, or 
medium only (negative control). For evaluation of bosentan also HuH-7 human hepatoma 
cells were used. Comparable to rifampicin, bosentan was a moderate to strong inductor for 
all cytochrome P450 isozymes and ATP-binding cassette transporters tested, and it also 
induced organic anion transporting polypeptides. In contrast, ambrisentan only weakly 
induced some of the genes investigated in LS180 cells. These findings corroborate the in 
vivo finding that bosentan is much more prone to drug interactions than ambrisentan. 
6. JudyW.M.Chenget.al.,20 demonstrated the role of Ambrisentan for the            
Management of Pulmonary Arterial Hypertension. The available clinical data suggest that 
ambrisentan is an effective and well-tolerated therapy for the management of PAH 
7. Ronald J.Oudizet.al.,21 made a study on Long-Term Ambrisentan Therapy for the 
Treatment of Pulmonary Arterial Hypertension. After 2 years of ambrisentan exposure, the 
mean change from baseline in 6-min walk distance was improved for the 5-mg (23 m., 95% 
confidence interval: 9 to 38 m) and 10-mg (28 m., 95% confidence interval: 11 to 45 m) 
groups. Two years of ambrisentan treatment was associated with sustained improvements in 
exercise capacity and a low risk of clinical worsening and death in patients with PAH. 
Ambrisentan was generally well tolerated and had a low risk of aminotransferase 
abnormalities over the 2-year study period. 
 Department of Pharmaceutical Analysis 2016 
 
C. L. Baid Metha College of Pharmacy Page 33 
 
8. J. Dupuis et.al.,22 investigated the role of Endothelin receptor antagonists in   Pulmonary 
arterial hypertension. The endothelin (ET) system, especially ET-1 and the ETA and ETB 
receptors, has been implicated in the pathogenesis of pulmonary arterial hypertension 
(PAH). Together with prostanoids and phosphodiesterase 5 inhibitors, ET receptor 
antagonists have become mainstays in the current treatment of PAH. Three substances are 
currently available for the treatment of PAH. One of these substances, bosentan, blocks both 
ETA and ETB receptors, whereas the two other compounds, sitaxsentan and ambrisentan, 
are more selective blockers of the ETA receptor. 
9. MichaelD.McGoonet.al.,23made a study on ambrisentan therapy in patients with 
pulmonary arterial hypertension who Discontinued Bosentan or Sitaxsentan Due to Liver 
Function Test Abnormalities. Patients who previously discontinued bosentan and/or 
sitaxsentan due to LFT abnormalities received ambrisentan, 2.5 mg qd, for 4 weeks 
followed by 5 mg/d for 8 w.eeks. The primary end point was the incidence of 
aminotransferase levels more than three times ULN considered by the investigator to be 
related to ambrisentan and resulting in drug discontinuation. Secondary end points included 
aminotransferase levels more than five times ULN requiring drug discontinuation and more 
than three times ULN requiring dose reduction, as well as changes in 6-min walk distance 
(6MWD 
10. Nazzareno Galièet.al.,24 conducted Randomized, Double-Blind, Placebo-Controlled, 
Multicenter, Efficacy (ARIES) tests in  patients receiving ambrisentan for PAH therapy and 
concluded that Ambrisentan improves exercise capacity in patients with pulmonary arterial 
hypertension and it is is well tolerated and is associated with a low risk of aminotransferase 
abnormalities. 
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11. BrianCasserlyet.al.,25 conducted a study on role of Ambrisentan in the treatment of 
pulmonary arterial hypertension and concluded that Ambrisentan appears to be a safe and 
efficacious treatment for PAH patients in WHO functional class II or III. 
12. Rebecca Spence et.al.,26 reported the pharmacokinetics and Safety of Ambrisentan in 
combination with Sildenafil in Healthy Volunteers. The pharmacokinetic interaction 
between sildenafil, and ambrisentan, was studied in a 2-period crossover study in 19 healthy 
volunteers, with ambrisentan exposure (AUC0-∞) and Cmax determined over 24 hours for a 
10-mg dose of ambrisentan alone and again after 7 days of sildenafil 20 mg 3 times daily. 
The AUC0-∞ and Cmax for sildenafil and N-desmethyl sildenafil (active metabolite) were 
determined over 24 hours for a 20-mg dose of sildenafil alone and again after 7 days of 
dosing with ambrisentan 10 mg once daily. There was no clinically relevant 
pharmacokinetic interaction between ambrisentan and sildenafil or N-desmethyl sildenafil. 
13. Gennyne Walker et.al.,27 conducted the pharmacokinetics and pharmacodynamics of 
warfarin in combination with ambrisentan in healthy volunteers. Twenty two healthy 
subjects were administered a single dose of racemic warfarin 25 mg alone and after 8 days 
of ambrisentan 10 mg once daily. Assessments included exposure (AUC0–last) and 
maximum plasma concentration (Cmax) for R and S-warfarin, and International Normalized 
maximum observerved value (INRmax) and area under the curve (INRAUC(0–
last)).Ambrisentan had no significant effects on the (AUC0–last)of R-warfarin or S-warfarin. 
In addition, coadministration of warfarin did not alter ambrisentan steady-state 
pharmacokinetics. Adverse events were infrequent, and there were no bleeding adverse 
events. 
14. HartmutVatteret.al.,28 demonstrated the role of ambrisentan as a Non-peptide 
Endothelin Receptor Antagonist, concluded that because of convenient physiological and 
pharmacological properties and its good tolerability ambrisentan will probably play an 
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essential role in the therapy of diseases, for which a potent ETA-receptor antagonist with a 
moderate selectivity is the most customized approach.  
15. Ori Ben-Yehuda et.al.,29 conducted a study on Long-Term Hepatic Safety of 
Ambrisentan in Patients With Pulmonary arterial hypertension. No evidence of an 
association between ambrisentan therapy and hepatotoxicity was identified  
16. Rebecca Spence et.al.,30 reported the Pharmacokinetics and Safety interactions  of 
Ambrisentan in Combination With Taldafil in Healthy Volunteers. Single-dose PK of 
ambrisentan (10 mg) and its metabolite, 4-hydroxymethyl ambrisentan, were determined in 
the absence and presence of multiple doses of tadalafil (40 mg QD). Similarly, single-dose 
PK of tadalafil (40 mg) were evaluated in the absence and presence of multiple doses of 
ambrisentan (10 mg QD). In the presence of tadalafil, ambrisentan maximum plasma 
concentration (Cmax) was similar and systemic exposure (AUC0–∞) was slightly decreased 
compared with ambrisentan alone.  
17. M. Halanket.al.,31 conducted a study on patients with ambrisentan therapy and 
concluded that Ambrisentan Improves Exercise Capacity and Symptoms in Patients with 
Portopulmonary Hypertension. No significant changes in blood gas analysis and liver 
function tests (aspartate aminotransferase, alanine aminotransferase, total bilirubin, and 
international normalized ratio) during therapy with ambrisentan were detectable. 
18.J.Craig Hartman et.al.,33 Evaluated the endothelin receptor antagonists ambrisentan, 
darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary 
transporters in sandwich-cultured human hepatocytes, and concluded that Bosentan and 
Sitaxsentan ,but not Darusentan and Ambrisentan inhibit human hepatic transporters which 
provides a potential mechanism for the increased hepatotoxicity. 
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3.1  AIM & OBJECTIVE OF WORK 
The drug analysis plays an important role in the development of new analytical 
methods, their manufacture and the therapeutic use. Pharmaceutical industries rely upon 
quantitative chemical analysis to ensure that the raw materials used and the final product 
obtained meets the required specification. The components monitored include chiral or 
achiral drug process impurities, residual solvents excipents such as preservatives, 
degradation products, extractable and leachable  matterfrom containers and closuresetc. 
Ambrisentan is indicated for the treatment of patients with pulmonaryarterial 
hypertension (PAH) classified as World Health organisation (WHO) functionalclass (FC) II 
and III, to improve exercise capacity. Ambrisentan, is a propanoic acid-classan endothelin 
receptor antagonist that isselective for the endothelin type-A (ETA) receptor. It is a Bio 
pharmaceutics Classification System Type II drug.It has a low potential for drug-drug 
interactions when compared to other endothelin receptor antagonists and requires only once-
daily administration. 
The extensive literature survey reveals that no method has been developed for the 
estimation of Ambrisentan in tablet dosage form. The objective of the present work is to 
develop a specific, precise, accurate, linear, simple, rapid and validated RP-HPLC method 
forAmbrisentan. 
The specific aim of the research was  
 To develop a RP-HPLC method for determination of Ambrisentan in tablet dosage 
form.  
 Validate the optimized method in accordance with ICH guidelines for the intended 
analytical application.  
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3.2 PLAN OF WORK 
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Summary and Conclusion
    
 
 
 
 
 
 
 
 
Results and Discussion 
 
Validation as per ICH 
guidelines  
 Specificity 
 Linearity and range 
 Accuracy 
 Precision 
 LOD 
 LOQ 
 Robustness 
 System suitability 
Assay 
Selection of best trials 
Experimental investigation (Method Development) 
 Selection of column 
 Selection of mobile phase 
 Selection of chromatographic conditions 
 Optimization of chromatographic and spectral 
conditions 
 
Materials and methods 
Literature review 
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4. DRUG PROFILE35 
Ambrisentan 
Chemical formula :C22H22N2O. 
Structure  : 
 
Chemical name :(2S)-2-[(4, 6-dimethylpyrimidin-2-yl) oxy]-3-methoxy- 3, 3-
diphenylpropanoic acid 
Molecular weight : 378.421gm/mol 
Description  : white to off-white crystalline substance. 
Solubility : Insoluble in water (0.06 mg/ml) and soluble in aqueoussolutions of 
high pH 
PKa   : 4.0 
Category  :Endothelin type A (ETA)-selective receptor antagonist 
Dose   :5 or 10 mg in tablet  
Mechanism of action36 
Ambrisentan is an orally active, propanoic acid-class, endothelin receptor antagonist 
(ERA) that is selective for the endothelin type A (ETA) receptor. Selective inhibition of the 
ETA receptor inhibits phospholipase C-mediated vasoconstriction and protein kinase C-
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mediated cell proliferation, while preserving nitric oxide and prostacyclin production, cyclic 
GMP- and cyclic AMP-mediated vasodilation, and endothelin-1 (ET-1) clearance that is 
associated with the endothelin type B (ETB) receptor. 
Pharmacokinetics 36 
Absorption 
The absolute bioavailability of ambrisentan is not known. Ambrisentan is absorbed 
rapidly in humans. After oral administration, maximum plasma concentrations (Cmax) of 
ambrisentan typically occur between 539-1147 ng/ml around 1.5 hours post dose under both 
fasted and fed conditions.37Cmax and area under the plasma concentration-time curve 
(AUC) increase dose proportionally over the therapeutic dose range. Steady-state is 
generally achieved following 4 days of repeat dosing.  
Distribution 
Ambrisentan is highly plasma protein bound. The in vitro plasma protein binding of 
ambrisentan was on average 98.8% and independent of concentration over the range of 0.2 – 
20 microgram/mL. Ambrisentan is primarily bound to albumin (96.5%) and to a lesser 
extent to alpha1-acid glycoprotein.  
The distribution of ambrisentan into red blood cells is low, with a mean blood:plasma ratio 
of 0.57 and 0.61 in males and females, respectively.  
Metabolism 
Ambrisentan is excreted largely unchanged (45.6% of the dose). Ambrisentan is 
glucuronidated via several UGT isoenzymes (UGT1A9S, UGT2B7S, and UGT1A3S) to 
form ambrisentanglucuronide (13%). Ambrisentan also undergoes oxidative metabolism 
mainly by CYP3A4 and to a lesser extent by CYP3A5 and CYP2C19 to form 4-
hydroxymethyl ambrisentan (21%) which is further glucuronidated to 4-hydroxymethyl 
ambrisentanglucuronide (5%). The binding affinity of 4-hydroxymethyl ambrisentan for the 
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human endothelin receptor is 65-fold less than ambrisentan. Therefore at concentrations 
observed in the plasma (approximately 2% relative to parent ambrisentan), 4-hydroxymethyl 
ambrisentan is not expected to contribute to pharmacological activity of ambrisentan. 
Excretion 
Ambrisentan and its metabolites are eliminated primarily in the bile following 
hepatic and/or extra-hepatic metabolism with approximately 66% of the oral dose excreted 
in the faeces, the majority of which is unchanged ambrisentan (41% of the dose). 
Approximately 22% of the administered dose is recovered in the urine following oral 
administration with 3.3% being unchanged ambrisentan. Plasma elimination half-life in 
humans ranges from 13.6 to 16.5 hours. 
Half-life: 15 hr terminal; 9 hr effective 
INDICATIONS  
Ambrisentan is indicated for the treatment of:  
 Idiopathic pulmonary arterial hypertension (PAH),  
 Pulmonary arterial hypertension associated with connective tissue disease (PAH-
CTD),  
 In patients with WHO functional class II, III or IV symptoms.  
CONTRAINDICATIONS  
Ambrisentan is contraindicated in 
 Pregnancy  
Ambrisentan is a category X drug and must not be given to pregnant women. 
Pregnancy must be avoided during treatment and for at least 3 months following 
cessation of treatment with this drug. 
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 Women of child-bearing potential who are not using reliable contraception. Women 
must not become pregnant for at least 3 months after stopping treatment with 
ambrisentan.  
 Patients with severe hepatic impairment (with or without cirrhosis) . 
 Patients with baseline values of hepatic aminotransferases (aspartate 
aminotransferase [AST] and/or alanine aminotransferase [ALT]) greater than 3 
times the Upper Limit of Normal (ULN)  
 Patients who exhibit or may exhibit hypersensitivity to ambrisentan 
Possible side effects38 
Ambrisentan is expected to provide optimal results in the treatment of PAH. However, like 
all drugs, there are certain side effects that can be expected when undergoing Ambrisentan 
drug treatments, the most common of which is the occurrence of a headache. Ambrisentan 
patients also face the risk of developing liver function abnormalities; thus far, there has been 
a low incidence of this side effect in clinical trial testing. 
 Hepatic 
Hepatic side effects have included dose-dependent liver injury manifested primarily by 
elevation of serum aminotransferases (ALT or AST), but sometimes accompanied by 
abnormal liver function (elevated bilirubin). The combination of aminotransferases greater 
than 3 times the upper limit of normal and total bilirubin 2 times the upper limit of normal is 
a marker for potentially serious hepatic injury. 
 Hematologic 
Hematologic side effects have included decreases in hemoglobin concentration and 
hematocrit. Post marketing reports have included anemia. There have been post marketing 
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reports of decreases in hemoglobin concentration and hematocrit that have resulted in 
anemia requiring transfusion. In the long-term open-label extension of the two pivotal 
clinical studies, mean decreases from baseline (ranging from 0.9 to 1.2 g/dL) in hemoglobin 
concentrations persisted for up to 4 years of treatment. 
 Cardiovascular 
Cardiovascular side effects have included peripheral edema, palpitations, and flushing. Fluid 
retention has been reported during post marketing use of Ambrisentan. Additional post 
marketing reports have included heart failure (associated with fluid retention). 
 Respiratory 
Respiratory side effects have included dyspnea, nasal congestion, sinusitis, and 
nasopharyngitis. 
 Gastrointestinal 
Gastrointestinal side effects have included abdominal pain and constipation.     Post 
marketing experience has included nausea and vomiting. 
 Nervous system 
Nervous system side effects have included headache. 
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5.   MATERIALS & EQUIPMENTS 
 
6.1     List of materials used for method development 
For the determination of Ambrisentan in tablet dosage form by RP-HPLC method the 
following instruments were used. 
Table:3 List of Instruments 
S. No. Name Model Manufacturer 
1 
2 
3 
4 
HPLC with VWD detector 
PH meter 
Sonicator 
Analytical balance 
      LC1200 
              - 
- 
BSA2245-CW 
Agilent Technologies 
Eutech 
Remi Instruments 
Sortorius 
 For the determination of Ambrisentan in tablet dosage form by RP-HPLC method 
the following chemicals were used. 
Table:4 List of Chemicals 
S. No. Name Grade Manufacturer 
1 
2 
3 
4 
Potassium Dihydrogen Orthophosphate 
Phosphoric acid 
Acetonitrile 
Milli Q water 
AG 
AG 
HPLC 
HPLC 
Fischer scientific 
Fischer scientific 
Fischer scientific 
In House production 
 For the determination of Ambrisentan in tablet dosage form by RP-HPLC method 
the following Standard drugs were used as a reference standard. 
Table: 5 List of Standard drugs 
S. No. Name Specification purity % Procured from 
1 Ambrisentan WS 99.5 
Gift Sample from MSN 
Laboratories Ltd, India 
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The following marketed formulation was used for the determination of purity of 
Ambrisentan in tablet dosage form by RP-HPLC method, 
Table: 6 Marketed formulation 
Brand name Label claim Manufacturing company  
 
ENDOBLOC 
 
 
                   Ambrisentan 
(5mg) 
+ 
Excipients (qty specified) 
 
MSN LABORATORIES 
LTD,INDIA 
 For the determination of Ambrisentan in tablet dosage form by RP-HPLC method 
the following apparatus were used. 
Table:7 List of Apparatus  
S.No. Apparatus Manufacturing  
1 
2 
3 
4 
5 
6 
7 
8 
Beakers 
Pipettes 
Measuring cylinders 
Volumetric flasks 
Glass rods 
Spatula 
Rubber bulbs 
Filter papers(0.45µ) 
Borosil 
Borosil 
Borosil 
Borosil 
- 
- 
- 
Whatmann 
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6. ANALYTICAL METHOD DEVELOPMENT 
A good method development strategy should require only as many experimental runs as are 
necessary to achieve the desired final result. Finally method development should be as 
simple as possible, and it should allow the use of sophisticated tools such as computer 
modeling. The important factors, which are to be taken into account to obtain reliable 
quantitative analysis, are 
a). Careful sampling and sample preparation. 
b). Precise sample injection. 
 c). Appropriate choice of the column. 
d). Choice of the operating conditions to obtain the adequate resolution of  mixture 
e). Reliable performance of the recording and data handling systems. 
f). Suitable integration/peak height measurement techniques. 
g). the mode of calculation best suited for the purpose. 
 h). Validation of the developed method.  
Preparation of Standard drug solution 
Approximately 25mg of Ambrisentan was weighed and transferred into50mL volumetric 
flask, diluted to 30 ml with mobile phase and sonicated for 15minutes. Then the volume was 
made up to 50mL with mobile phase and filtered through 0.45µ membrane filter. Further 
5mL of above solution was diluted to 25 ml and mixed to get a concentration of 100 µg/ml. 
6.1 Analytical Method development trials 
Trial No.1 
Mobile phase preparation 
The mobile phase was prepared by mixing HPLC grade methanol and water in the ratio 
50:50 v/v. Then it was sonicated and filtered through 0.45µ membrane filter. 
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Chromatographic conditions 
Standard solution of Ambrisentan was loaded in the vial, injected and run for 30 min. The 
HPLC parameters were set in the method as follows. 
 Column  :Kromosil C18, 250×4.6 mm, 5µm  
 Column temperature : Ambient 
 Mobile Phase  : Methanol: water (80:20 v/v)  
 Flow rate  : 1mL/min 
 Injection volume : 10µL 
 Wave length  : 210nm 
 Run time  : 30min 
Figure 7: HPLC chromatogram for first trial 
Table: 9 Results for trial 1 
Drug Retention time Tailing factor Theoretical plates 
Ambrisentan. ------ ------ ------ 
 
Discussion 
No peak was eluted so the mobile phase has been changed for next trail. 
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Trial No.2 
Mobile phase preparation 
The mobile phase was prepared by mixing HPLC water and Acetonitrile in the ratio 50:50 
v/v. Then it was sonicated and filtered through 0.45µ membrane filter. 
Chromatographic conditions 
Standard solution of Ambrisentan was loaded in the vial, injected and run for 30min. The 
HPLC parameters were set in the method as follows. 
 Column                    : KromosilC18,250×4.6mm, 5µm  
 Column temperature   : Ambient 
 Mobile Phase   :  Acetonitrile: water(50:50 v/v) 
 Flow rate                   :  1mL/min 
 Injection volume       :  10µL 
 Wave length              :  210nm 
Figure8: HPLC chromatogram for second trial 
Table: 10 Results for trial 2 
Drug Retention time Tailing factor Theoretical plates 
Ambrisentan. ------ ------ ------ 
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Discussion 
No peak was eluted so the mobile phase has been changed for next trail. 
Trial No.3 
Preparation of Buffer 
2.72 gms of potassium dihydrogen orthophosphate is dissolved in 1000 ml of water and pH 
is adjusted to 3.5±0.05 with dilute ortho-phosphoric acid, then sonicated and filtered 
through 0.45µ membrane filter. 
Mobile phase preparation 
The mobile phase was prepared by mixing mobile phase A:B in the ratio of 50:50 v/v.The 
mobile phase A is potassium dihydrogen orthophosphate buffer and mobile phase Bis 
Acetonitrile: water (90:10 v/v), then sonicated and filtered through 0.45µmembrane filter. 
Chromatographic conditions 
Standard solution of Ambrisentan was loaded in the vial, injected and run for 30min. The 
HPLC parameters were set in the method as follows. 
 Column  : KromosilC18,  250×4.6 mm, 5µm  
 Column temperature : 350C 
 Mobile phase  : A:B(50:50 v/v) 
Mobile phase A : Potassium dihydrogen orthophosphate buffer (pH 3.5) 
Mobile phase B : Acetonitrile: water (90:10 v/v) 
 Flow rate  : 1mL/min 
 Injection volume :10µL 
 Wave length  : 210nm 
. 
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Figure 9: HPLC chromatogram for third trial 
Table: 11 Results for trial 3 
Drug Retention time Tailing factor Theoretical plates 
Ambrisentan. 6.63 2.97 10512 
 
Discussion 
The analyte peak was well eluted but noise was observed in the base line. The remaining 
suitability parameters were also not within the limits. 
Trial No.4 
Preparation of Buffer 
2.72 gms of potassium dihydrogen orthophosphate is dissolved in 1000 ml of water and pH 
is adjusted to 3.5±0.05 with diluted phosphoric acid , then sonicated and filtered through 
0.45µ membrane filter. 
Mobile phase preparation 
The mobile phase was prepared by mixing mobile phase A:B in the ratio of 40:60 v/v. The 
mobile phase A is potassium dihydrogen orthophosphate buffer and mobile phase B is 
Acetonitrile:Water (90:10v/v), then sonicated and filtered through 0.45µ membrane filter. 
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Chromatographic conditions 
Standard solution of Ambrisentan was loaded in the vial, injected and run for 10min. The 
HPLC parameters were set in the method as follows. 
 Column  : Kromosil C18,  250×4.6mm, 5µm 
 Mobile phase  : A:B(40:60 v/v) 
Mobile phase A : Potassium dihydrogen orthophosphate buffer (pH 3.5) 
Mobile phase B : Acetonitrile: water (90:10 v/v) 
 Column temperature :  350C 
 Flow rate  : 1mL/min 
 Injection volume : 10µL 
 Wave length  : 210nm 
 
Figure10: HPLC chromatogram for fourth trial 
Table: 12 Results for trial 4 
Drug Retention time Tailing factor Theoretical plates 
Ambrisentan 5.75 2.25 7653 
 
Discussion 
The analyte peak was well eluted but the suitability parameter was not within the limits. 
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Trial No.5 
Preparation of Buffer 
2.72 gms of potassium dihydrogen orthophosphate is dissolved in 1000 ml of water and pH 
is adjusted to 3.±0.05 with dilute phosphoric acid, then sonicated and filtered through 0.45µ 
membrane filter. 
Mobile phase preparation 
The mobile phase was prepared by mixing mobile phase A: B in the ratio of 40:60 v/v.The 
mobile phase A is potassium dihydrogen orthophosphate buffer and mobile phase B is 
Acetonitrile: water (90:10v/v).Then sonicated and filtered through 0.45µ membrane filter. 
Chromatographic conditions 
Standard solution of Ambrisentan was loaded in the vial, injected and run for 10min. The 
HPLC parameters were set in the method as follows. 
 Column                       :  Kromosil C18,  250×4.6 mm, 5µm 
 Mobile phase  :  A:B(40:60 v/v) 
Mobile phase A  :  Potassium dihydrogen orthophosphate buffer (pH 3.0) 
Mobile phase B :  Acetonitrile: water (90:10 v/v) 
 Column temperature  :  Ambient 
 Flow rate                    :  1mL/min 
 Injection volume        :  10µL 
 Wave length               :  210nm 
 Run time  : 10min 
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Figure 11: HPLC chromatogram for fifth trial 
Table: 13 Results for trial 5 
Drug Retention time Tailing factor Theoretical plates 
Ambrisentan 5.28 2.45 6509 
 
Discussion 
The elution of the analyte peak was satisfactory but the system suitability parameter was not 
within the limits. 
Trial No.6 
Analytical method development optimization 
Preparation of Buffer 
2.72 gms of potassium dihydrogen orthophosphate is dissolved in 1000 ml of water and pH 
is adjusted to 3.±0.05 with dilute phosphoric acid, then sonicated and filtered through 0.45µ 
membrane filter. 
Mobile phase preparation 
The mobile phase was prepared by mixing mobile phase A: B in the ratio of 30:70 v/v.The 
mobile phase A is potassium dihydrogen orthophosphate buffer and mobile phase B is 
Acetonitrile: water (90:10v/v), then sonicated and filtered through 0.45µ membrane filter. 
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Figure 12: HPLC chromatogram for sixth trial 
Table: 14 Results fortrial 6 
Drug Retention time Tailing factor Theoretical plates 
Ambrisentan 4.82 0.85 11509 
 
Discussion 
The analyte peak was well eluted and all the system suitability parameters are within the 
acceptable limits. Hence this method is considers as optimized and validated as per ICH 
guidelines. 
6.2 Optimized Analytical Method 
So after six trials it has been observed that trial 6 was optimized method for carry out the 
validation of Ambrisentan in marketed tablet formulation. Chromatographic condition for 
optimized method are given below  
Chromatographic conditions 
Standard solution of Ambrisentan was loaded in the vial. The HPLC parameters were set in 
the method as per table 8, injected and run for 10 min. 
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Table: 8 Chromatographic Conditions 
PARAMETERS DESCRIPTION 
Column 
Temperature 
Mobile phase   
Mobile phase A   
Mobile phase B 
Flow Rate 
Injection Volume 
Detector wave length 
Run time 
KromosilC18, 250×4.6 mm, 5µm 
350C 
A:B(30:70) 
Potassium dihydrogen orthophosphate buffer of pH 3.0±0.05 
ACN:Water (90:10) 
1.0 ml/min 
10µL 
210nm 
10 min 
 
6.3 Assay  
Procedure of the preparation of standard solution & sample solution 
6.3.1 Preparation of working standard solution 
Approximately 25mg of Ambrisentan (WS) was weighed and transferred into50mL 
volumetric flask, diluted to 30 ml with mobile phase and sonicated for 15minutes. 
Then the volume was made up to 50mL with mobile phase and filtered through 
0.45µ membrane filter. Further 5ml of above solution was diluted to 25 ml and 
mixed to get a concentration of 100 µg/ml. 
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6.3.2 Preparation of sample solutions 
20 tablets were powdered and weigh and transfer tablet powder equivalent to 50 mg of 
Ambrisentan into 50 ml volumetric flask, diluted to 30 ml with mobile phase and 
sonicated for 15 mins and diluted to volume and filtered through 0.45µ membrane 
filter. Further dilute 5 ml of this solution to 25 ml with mobile phase and mixed to get 
a concentration of 100 µg/ml. 
Calculation: 
The amount of Ambrisentan present in marketed formulation each tablet was calculated by 
using the following formula: 
𝐀𝐦𝐨𝐮𝐧𝐭 𝐩𝐫𝐞𝐬𝐞𝐧𝐭 
=
Sample Area
Standard Area
 X 
Standard  weight
Standard  Dilution
 X 
Sample Dilution
Sample weight
X
WS purity
100
 X Average weight 
𝐀𝐬𝐬𝐚𝐲 =
Amount present
Label Claim
 X 100 
Average weight of 20 tablets = 91.6 mg. 
Weight taken = 461.2 mg. 
Label claim: 5 mg of Ambrisentan.    
 
Figure 13: HPLC chromatogram of Ambrisentan for marketed formulation 
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S. No Name RT Area Plate count Tailing 
1 Ambrisentan 4.82 74991596 11087 0.91 
 
Table.9 Tabular Column for the Assay of Marketed formulation 
S. No Weight 
taken 
Sample area Standard 
area 
Content/Tablet 
in mg 
Percentage 
purity 
1 461.2 mg 74991596 75174299 5.01 100.25 
 
Discussion 
The percentage purity of Ambrisentan in tablet dosage form was calculated. The percentage 
purity was found of Ambrisentan was found to be 100.25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Department of Pharmaceutical Analysis 2016 
 
C. L. Baid Metha College of Pharmacy Page 57 
 
7. VALIDATION OF DEVELOPED METHOD 
7.1 PREPARATION OF SOLUTION 
7.1.1 Preparation of Phosphate Buffer Solution 
2.72 gms of potassium dihydrogen orthophosphate is dissolved in 1000 ml of water 
and pH is adjusted to 3.±0.05 with dilute phosphoric acid, then sonicated and filtered 
through 0.45µ membrane filter. 
 
7.1.2 Preparation of mobile phase 
The mobile phase was prepared by mixing mobile phase A: B in the ratio of 30:70 
v/v.The mobile phase A is potassium dihydrogen orthophosphate buffer and mobile 
phase B is Acetonitrile: water (90:10v/v), then sonicated and filtered through 0.45µ 
membrane filter 
7.1.3 Preparation of working standard solution 
Approximately 25mg of Ambrisentan (WS) was weighed and transferred into50mL 
volumetric flask, diluted to 30 ml with mobile phase and sonicated for 15minutes. 
Then the volume was made up to 50mL with mobile phase and filtered through 0.45µ 
membrane filter. Further 5ml of above solution was diluted to 25 ml and mixed to get 
a concentration of 100 µg/ml. 
7.1.4 Preparation of sample solutions 
20 tablets were powdered and weigh and transfer tablet powder equivalent to 50 mg of 
Ambrisentan into 50 ml volumetric flask, diluted to 30 ml with mobile phase and 
sonicated for 15 mins and diluted to volume and filtered through 0.45µ membrane 
filter. Further dilute 5 ml of this solution to 25 ml with mobile phase and mixed to get 
a concentration of 100 µg/ml. 
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The amount of Ambrisentan present in each tablet was calculated by using the following 
formula: 
Amount present 
=
Sample Area
Standard Area
 X 
Standard  weight
Standard  Dilution
 X 
Sample Dilution
Sample weight
X
Percentage purity
100
 X Average weight 
% Amount present =
Amount present
Label Claim
 X 100 
7.2 ANALYTICAL METHOD VALIDATION 
The developed method was validated according to ICH guidelines 
 
Method validation of Ambrisentan  
The mobile phase was prepared and all parameters were set as per the above optimized 
method. 
7.2.1 Specificity 
Ambrisentan Identification 
Solutions of standard and Sample were prepared as per test method and injected into the 
chromatographic system.  
Acceptance criteria 
Chromatogram of Standard and sample should be identical with near/same retention time.  
Blank interference 
A study to establish the interference, blank detection was conducted. Mobile phase was 
injected as per the test method.  
Acceptance criteria 
Chromatogram of blank did not show any peak at the retention time of analyte peak. 
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The blank, placebo, standard and sample solutions were injected into the chromatograph and 
the chromatograms ware recorded and presented below. 
 
Figure 14: HPLC Chromatogram of blank (mobile phase) 
Drug Retention time Tailing factor Theoretical plates 
Ambrisentan ------ ------ ------ 
 
 
Figure 15: HPLC chromatogram of Placebo 
Drug Retention time Tailing factor Theoretical plates 
Ambrisentan ------ ------ ------ 
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Figure 16: HPLC chromatogram of standard Ambrisentan 
Drug Retention time Tailing factor Theoretical plates 
Ambrisentan 4.82 0.85 11509 
 
 
Figure 17: HPLC chromatogram of sample  
Drug Retention time Tailing factor Theoretical plates 
Ambrisentan 4.82 0.81 11091 
 
Observation :    No peaks were found at retention time 4.82 min  
Discussion :  As no peaks were found at retention time of 4.82 min the proposed 
method was specific for the detection of Ambrisentan. 
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7.2.2  Linearity and Range 
The linearity of calibration curves in standard solution was checked over the concentration 
ranges of about 50-140 μg/ml for Ambrisentan. The total eluting time was less than 5min. 
The linearity plot is shown in fig 17. 
The peak area and concentration were plotted to get a standard calibration curve. The 
correlation coefficient and regression coefficient were calculated. 
Linearity 50%  
Figure 18: HPLC chromatogram of Ambrisentan for linearity 50%. 
S.No Conc.(µg/ml) Name RT Area Platecount Tailing 
1 50 Ambrisentan 4.82 38232397 10930 0.85 
 
Linearity 60% 
Figure 19: HPLC chromatogram of Ambrisentan for linearity 60%. 
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S. No Conc(µg/ml) Name RT Area Platecount Tailing 
1 60 Ambrisentan 4.82 45520461 11564 0.93 
 
Linearity 80% 
 
Figure 20: HPLC chromatogram of Ambrisentan for linearity 80%. 
S.No Conc.(µg/ml) Name RT Area Platecount Tailing 
1 80 Ambrisentan 4.82 60179623 11512 0.97 
 
Linearity 100% 
Figure 
21: HPLC chromatogram of Ambrisentan linearity 100 %. 
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S.No Conc.(µg/ml) Name RT Area Platecount Tailing 
1 100 Ambrisentan 4.82 76181304 11465 0.95 
 
Linearity 120% 
Figure 22: HPLC chromatogram of Ambrisentan linearity 120 % 
S.No Conc.(µg/ml) Name RT Area Platecount Tailing 
1 120 Ambrisentan 4.82 91097774 11504 0.83 
 
Linearity 150% 
Figure 23: HPLC chromatogram of Ambrisentan linearity 150 % 
S.No Conc.(µg/ml Name RT Area Platecount Tailing 
1 150 Ambrisentan 4.82 107102232 11697 0.92 
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Figure 24: Linearity plot of Ambrisentan 
 
Table: 10 Linearity of Ambrisentan 
S .NO CONC. (%) AREA 
1.  50 38232397 
2.  60 45520461 
3.  80 60179623 
4.  100 76181304 
5.  120 91097774 
6.  150 115277625 
 
Acceptance criteria: Correlation coefficient  0.997 
Discussion The linearity of the method was demonstrated over the concentration range of 
50-150 μg/ml for Ambrisentan. The calibration curve for Ambrisentan was plotted. The 
correlation coefficient for Ambrisentan was found to be 0.999. 
7.2.3 Accuracy 
Accuracy of the method was determined by recovery experiments. Recovery study can be 
carried out by spiking study or swab study (usually for cleaning validation). In my 
experiment I performed by spiking method. To the formulation, the reference standards of 
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the drug were added at the level of 50%, 100%, 150%. The recovery studies were carried 
out by triplicate injection and the percentage recovery and percentage relative standard 
deviation were calculated and shown in table 17. 
Accuracy 50% injection 1 
Figure 24: HPLC chromatogram of Ambrisentan for Accuracy 50% Inj (1) 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 37229585 11017 0.96 
 
Accuracy 50% injection 2 
 
Figure 25: HPLC chromatogram of Ambrisentan for Accuracy 50% Inj (2) 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 37532397 10978 0.81 
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Accuracy 50% injection 3 
Figure 26: HPLC chromatogram of Ambrisentan for Accuracy 50% Inj (3) 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 37235987 11126 0.97 
 
Accuracy 100% injection 1 
 
Figure 27: HPLC chromatogram of Ambrisentan for Accuracy 100% Inj (1) 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 75491039 11413 0.89 
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Accuracy 100% injection 2 
 
Figure 28: HPLC chromatogram of Ambrisentan for Accuracy 100% Inj (2) 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 76181304 11604 0.83 
 
Accuracy 100% injection 3 
Figure 29: HPLC chromatogram of Ambrisentan for Accuracy 100% Inj (3) 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 75914302 11369 0.79 
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Accuracy 150% injection 1 
Figure 30: HPLC chromatogram of Ambrisentan for Accuracy 150% Inj (1) 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 114088905 12239 0.85 
 
Accuracy 150% injection 2 
 
Figure 31: HPLC chromatogram of Ambrisentan for Accuracy 150% Inj (2) 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 114088905 12119 0.86 
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Accuracy 150% injection 3 
 
Figure 32: HPLC chromatogram of Ambrisentan for Accuracy 150% Inj (3) 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 115277625 12089 0.83 
 
Table: 11 Accuracy results for Ambrisentan 
Spiked 
Level 
Peak Area 
Amount Found In 
mcg/ml 
 
% Recovery 
%Mean 
Recovery 
 
% RSD 
50% 
50% 
50% 
37229585 
37532397 
37235987 
50.10 
50.45 
50.11 
99.22 
99.37 
99.02 
 
99 
 
0.46 
100% 
100% 
100% 
75491039 
76181304 
75914302 
101.60 
102.53 
102.17 
100.26 
100.74 
99.95 
 
100 
 
0.45 
150% 
150% 
150% 
114088905 
115277625 
114971209 
153.55 
155.15 
154.74 
100.25 
101.59 
101.61 
 
101 
 
0.53 
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The % recovery of the sample was calculated by the following formula-- 
% Recovery 
=
Actual calculated amount present in recovery sample
Amount spiked in to the recovery sample + Calculated theoritical preexisting amount
 X 100 
 
Acceptance Criteria 
The percentage recovery calculated should be between 98 to 102%. And % RSD of each 
level should not less than 2.0 
Discussion 
The percentage recovery of Ambrisentan was found 99%, 100% and 101% for accuracy 
50%, 100% and 150% samples respectively. The percentage RSD of the samples was also 
found less than 2. 
7.2.4 Precision 
Demonstrate the method precision by preparing six samples as per the test method of a 
single batch representing the 100% of test concentration. Determine the assay of these 
samples and evaluate the precision of the method by the % RSD of the assay results. The 
results were mentioned in table18. 
 
Precision injection 1 
Figure33: HPLC chromatogram of Ambrisentan for Precision Inj (1) 
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S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 74922610 11491 0.84 
 
Precision injection 2 
 
Figure 34: HPLC chromatogram of Ambrisentan for Precision Inj (2) 
S. No Name RT Area Plate count Tailing 
1 Ambrisentan 4.82 75155992 11097 0.93 
 
Precision injection 3 
 
Figure 35: HPLC chromatogram of Ambrisentan for Precision Inj (3) 
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S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.82 75403775 11219 0.87 
 
Precision injection 4 
Figure36: HPLC chromatogram of Ambrisentan for Precision Inj (4) 
S. No Name RT Area Plate count Tailing 
1 Ambrisentan 4.82 75169587 11157 0.91 
 
Precision injection 5 
 
Figure 37: HPLC chromatogram of Ambrisentan for Precision Inj (5) 
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S. No Name RT Area Plate count Tailing 
1 Ambrisentan 4.82 75219532 11329 0.87 
 
Precision injection 6 
 
Figure 38: HPLC chromatogram of Ambrisentan for Precision Inj (6) 
S. No Name RT Area Plate count Tailing 
1 Ambrisentan 4.82 75091152 11279 0.94 
 
Table: 12 Precision results for Ambrisentan 
Drug Concentration Peak Area Retention Time 
 
Ambrisentan 
(100 µg/ml) 
74922610 
75155992 
75403775 
75169587 
75219532 
75091152 
4.82 
4.82 
4.82 
4.82 
4.82 
4.82 
Standard Deviation 157588 NIL 
%RSD 0.45 NIL 
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Acceptance criteria: Percentage RSD ≤ 2 
Discussion 
The above precision study was assessed by repeatability tests. The % RSD for the area of 
Ambrisentan was found to be 0.45, which was well within the acceptance criteria limit. 
7.2.5 Limit of Detection & Limit of Quantitaton 
The LOD and LOQ of ESC and ETZ shall be estimated from the standard deviation of the 
response and the slope of the calibration curve by using the following formula 
     LOD =  
𝟑.𝟑×𝛔
𝐒
  LOQ =  
𝟏𝟎×𝛔
𝐒
  
 
Where   σ   = the standard deviation of the response 
  S   = the slope of the calibration curve 
Table 13: LOD & LOQ DETERMINATION 
Name Slope 
Standard deviation 
of response 
LOD 
(µg/ml) 
LOQ (µg/ml) 
Ambrisentan 770056 562962.7 4.51 13.68 
 
Report: The LOD & LOQ of Ambrisentan for this method were found to be 4.51 
µg/ml, and 13.68 µg/ml respectively. 
 
7.2.6 Robustness 
Robustness of the method was checked by small deliberate changes in the method 
parameters during the normal use. For this study flow rate, mobile phase composition, pH 
and temperature parameters were changed. The results were mentioned in table 19. 
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Robustness ((Flow 0.9ml/min) 
 
Figure39: HPLC chromatogram of Ambrisentan for robustness (Flow 0.9ml/min) 
S. No Name RT Area Plate count Tailing 
1 Ambrisentan 5.75 80823412 12239 1.18 
 
Robustness (Flow 1.1 ml/min) 
 
Figure 40: HPLC chromatogram of Ambrisentan for robustness (Flow 1.1 ml/min) 
S. No Name RT Area Plate count Tailing 
1 Ambrisentan 4.78 79878490 10930 1.23 
 
Table 14: Result of flow rate change 
S.No Flow Rate Retention Time Area 
1.  0.9 ml/minute 5.75 80823412 
2.  1 ml/minute 4.82 74991596 
3.  1.1 ml/minute 4.78 79878490 
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Robustness (Temp 30˚C) 
 
Figure 41: HPLC chromatogram of Ambrisentan for robustness (Temp 30˚C) 
S. No Name RT Area Plate count Tailing 
1 Ambrisentan 5.32 76014087 11432 1.18 
 
Robustness (Temp 40˚C) 
 
Figure 42: HPLC chromatogram of Ambrisentan for robustness (Temp 40˚C) 
S. No Name RT Area Plate count Tailing 
1 Ambrisentan 5.06 76292754 11629 1.18 
 
Table 15: Result of Column temperature change 
S.No Column temp. Retention Time Area 
1.  30˚C 5.32 76014087 
2.  Ambient 4.82 74991596 
3.  40˚C 5.06 76292754 
 
 Department of Pharmaceutical Analysis 2016 
 
C. L. Baid Metha College of Pharmacy Page 77 
 
Robustness (pH 2.8) 
 
Figure 43: HPLC chromatogram of Ambrisentan for robustness (pH2.8) 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.84 76275913 11089 1.21 
 
Robustness (pH 3.2) 
 
Figure 44: HPLC chromatogram of Ambrisentan for robustness (pH 3.2) 
 
S. No Name RT Area Platecount Tailing 
1 Ambrisentan 4.77 76656284 10966 1.27 
 
Table 16: Result of pH change 
S.No pH change Retention Time Area 
1.  pH 2.8 4.84 76275913 
2.  pH 2.8 4.82 74991596 
3.  pH 2.8 4.77 76656284 
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Robustness (M.P Variation -2%) 
 
Figure 45: HPLC chromatogram of Ambrisentan for robustness (M.P Variation -2%) 
S. No Name RT Area Plate count Tailing 
1 Ambrisentan 4.78 77025377 11380 1.16 
 
Robustness (M.P variation +2%) 
 
Figure 46: HPLC chromatogram of Ambrisentan for robustness (M.P variation +2%) 
S. No Name RT Area Plate count Tailing 
1 Ambrisentan 5.00 76656284 10966 1.27 
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Discussion: 
The robustness was tested by changing the flow, temperature, pH and mobile phase 
composition in the chromatographic parameters. The %RSD was found to be 0.83, 0.25, 
0.35, and 0.34 for flow, temperature, pH and mobile phase composition variation 
respectively. 
7.2.7 System Suitability 
Accurately 25mg of Ambrisentan was weighed and transferred into 50mL volumetric flask, 
diluted to 30 ml with mobile phase and sonicated for 15minutes. Then the volume was made 
up to 50mL and filtered through 0.45µ membrane filter. Further 5mL of above solution was 
diluted to 25 ml with mobile phase and mixed to get a concentration of 100 µg/ml. This 
Standard solution was injected in six replicate injections and the suitability parameters were 
calculated and given in table 20. 
This parameter was tested by giving six replicate injections of the sample to check the 
system suitability parameters like asymmetry, theoretical plates, tailing factor etc. 
Table.17 System suitability data of Ambrisentan 
Parameter Ambrisentan Acceptance criteria 
Theoretical plates 11916 >2000 
Tailing factor 0.84 <2 
Asymmetric factor 1.17 0.9-1.2 
 
Discussion 
The all system suitability parameters were within limits. The retention time for Ambrisentan 
was found to be 4.82 min.  
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7.2.8 Solution stability 
This parameter was performed to check the stability of the solution to give unaffected 
results over the course of time. Solution stability was performed after 24 and 48 hours 
 
Figure 47: HPLC chromatogram of Ambrisentan for solution stability after 24 hrs 
S. No Name RT Area Plate count Tailing Percentage purity 
1 Ambrisentan 4.93 75550735 11765 1.25 100.34 
 
 
Figure 48: HPLC chromatogram of Ambrisentan for solution stability after 48 hrs 
S.No Name RT Area Plate count Tailing Percentage purity 
1 Ambrisentan 4.94 75458298 12010 1.22 99.78 
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Discussion 
From the solution stability studies it was found that solution was stable up to 48 hours. The 
percentage recovery values were found to be 100.34 and 99.78 after 24 and 48 hours 
respectively.  
7.2.9 Assay for Marketed formulation 
Preparation of standard solution & sample solution 
Sample and standard solution were prepared both as per section 7.1.3 & 7.1.4  
 
Calculation: 
The amount of Ambrisentan present in marketed formulation each tablet was calculated by 
using the following formula: 
𝐀𝐦𝐨𝐮𝐧𝐭 𝐩𝐫𝐞𝐬𝐞𝐧𝐭 
=
Sample Area
Standard Area
 X 
Standard  weight
Standard  Dilution
 X 
Sample Dilution
Sample weight
X
WS purity
100
 X Average weight 
𝐀𝐬𝐬𝐚𝐲 =
Amount present
Label Claim
 X 100 
Average weight of 20 tablets = 91.6 mg. 
Weight taken = 461.2 mg. 
Label claim: 5 mg of Ambrisentan.    
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Figure 49: HPLC chromatogram of Ambrisentan for marketed formulation 
S. No Name RT Area Plate count Tailing 
1 Ambrisentan 4.82 74991596 11087 0.91 
 
Table.18 Tabular Column for the Assay of Marketed formulation 
S. No Weight 
taken 
Sample area Standard 
area 
Content/Tablet 
in mg 
Percentage 
purity 
1 461.2 mg 74991596 75174299 5.01 100.25 
 
Discussion 
The percentage purity of Ambrisentan in tablet dosage form was calculated. The percentage 
purity was found of Ambrisentan was found to be 100.25 
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8. SUMMARY 
On the basis of the experiments, the RP-HPLC method development of Ambrisentan was 
tried in Kromosil C18 column.The various mobile phase compositions were used in different 
ratios like methanol:water, Acetonitrile:water and Potassium 
dihydrogenorthophosphatebuffer:Acetonitrile. The various chromatographic conditions were 
tried to develop a method for analysis. Above all methods were compared and best method 
was selected for the development and validation of Ambrisentan in tablet dosage form. 
Ambrisentan was determined by reverse phase HPLC method using mobile phase A:B 
(30:70),mobile phase A is phosphate buffer (pH 3.0)and mobile phase B is 
Acetonitrile:water (90:10) by using a Kromosil ODS C18 Column, 5μ (250×4.6mm) as a 
stationary phase. Detection was carried out using VWD detector at 210 nm. After 
development of the method, it was validated for system suitability, specificity, linearity, 
limit of detection and limit of quantification, precision, accuracy, robustness and solution 
stability studies. 
The Specificity of Ambrisentan is shown in Chromatograms. There was no 
interference in this method and good separation between all peaks. It means no impurity was 
interfered and also reveals that commonly used excipients and additives present in the tablet 
dosage form were not interfering in the proposed methods. 
From the linearity table.16, it was found that, the drug obeys beer’s law. The 
calibration plot for Ambrisentan was observed as linear in the range of 50-150μg/ml and the 
correlation coefficient was found 0.999 .From the results shown in the accuracy table17, it 
was found that recovery values of pure drug from the solution were 98.0 % to 102 %, which 
indicates that the method is accurate. 
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The precision was found within the limits. The limits were not more than RSD 
2%.Precision RSD was 0.45 for Ambrisentan. This indicates that the method is precise. The 
data regarding the precision was shown in table18 respectively. 
Based on standard deviation response and slope the Limit of detection calculated for 
Ambrisentan was 0.124 µg/mL and Limit of quantitation calculated for Ambrisentan was 
0.370 µg/ml. 
In Robustness parameter, the change in flow, temperature, pH and mobile phase 
composition variation conditions the percentage R.S.D. was found less than 2%. Hence this 
method was better for method development in small deliberate changes. The data regarding 
robustness are shown in table 19. 
 The system suitability was found within the limits. The limit was not more than 
RSD 2%. The retention time of Ambrisentan was 4.82 min. The data regarding the system 
suitability are shown in table 20. 
During solution stability studies up to 48 hrs the percentage purity of Ambrisentan 
was within the acceptance criteria of 98-102% 
In assay of marketed formulation the percentage purity of Ambrisentan was100.25 
which indicates that the method can be used to determine the percentage purity of 
Ambrisentan in tablet dosage form. 
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8.2. CONCLUSION 
 
The proposed method  was found to be simple, accurate, precise and rapid RP-HPLC method 
suitable for the estimation of Ambrisentan in tablet dosage form. All the parameters meet the 
criteria of ICH guidelines for method validation and found to be simple, sensitive, accurate 
and precise. It can therefore be concluded that the reported method is more economical and 
can find practical application & may be recommended for routine and QC analysis of the 
investigated drugs to provide simple, accurate and reproducible quantitative analysis for the 
determination of Ambrisentan in tablet dosage form. 
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